Demeetra

Commercial licenses with freedom to operate

Expert support and knowledge transfer

The CRISPR/Cas9 licensing landscape is difficult to navigate, with no single licensor owning all rights. Demeetra's targeted nuclease patents differ from Cas9 as Cas-CLOVER™ uses a unique dimeric nuclease called Clo051. Our other core technology, piggyBac®, is a transposase and is unrelated to CRISPR/Cas9 licensing altogether.

Demeetra is the sole licensor for Cas-CLOVER in the fields of bioprocessing, agriculture, and synthetic biology; as well as piggyBac for synthetic biology and agriculture. Our IP portfolio includes globally and internally developed patents as well as internal know-how and trade secrets.

Demeetra provides:

- Flexible licensing bundles allowing for multiple paths to commercialization and freedom to operate
- Combine gene editing tools and licenses based on your needs
- Transfer of internal protocols, know-how, and expertise that have been proven by dozens of successful editing projects in cells, microbes, and plants

Global and internal gene editing IP, optimized by Demeetra, transferred to you

Kentucky, San Diego, Ireland, Germany

Kentucky
Technology improvements & novel applications, Demeetra

San Diego
Cas-CLOVER & hyperactive piggyBac, Poseida Therapeutics

Ireland
Synthetic sgRNAs and dCas9, **Optional CRISPR/Cas9 IP,** ERS Genomics

Germany
Clo051 nuclease, Helmholtz Munich

Partner with Demeetra

- Flexible licensing that supports commercialization
- Our know-how makes us more than a technology out-licensing company.



Excision-only piggyBac (footprint-free®)

Hyperactive piggyBac

Cas-CLOVER

Evaluation period supported by our expert scientists

Simplicity and clarity in technology licensing provided by our experienced business team

Own the IP you develop using our technology

Straightforward, one-time fee licensing structure

Upgrades to our technology by Demeetra are automatically added to your commercial license

Complete freedom to operate in bioproduction and agriculture

"We are very excited to improve the banana varieties preferred by farmers in Africa for disease-resistant bananas using Cas-CLOVER. The gene-edited banana with no foreign gene integration will not be regulated as a GMO in Kenya. The disease-resistant varieties will enhance banana production and increase the incomes of smallholder farmers in East Africa, where the banana is one of the major staple foods."

Leena Tripathi, Ph.D.,
Director of Eastern Africa Hub and Biotechnology Program Leader at International Institute of Tropical Agriculture (IITA)

"The flexibility of the guide RNA design makes the system easy to use and gives high specificity due to the use of the two guide RNAs. It is very efficient due to the ability of the dead Cas9s [dCas's] to recognize the current area of DNA, and since the Clo51 nuclease can only cut when dimerized, the system has high fidelity."

Kayla Bean, Ph.D.,
Research Scientist, Discovery Research Elanco Animal Health

Demeetra AgBio, Inc., holds the exclusive licenses for the gene editing technologies Cas-CLOVER and piggyBac transposase, for use in research and commercial applications in agriculture, synthetic biotechnology, and pharmaceutical bioprocessing.

Demeetra

Demeetra AgBio, Inc. | demeetra.com | Follow us
2277 Thunderstick Dr. #300 Lexington, KY 40505

Contact Us

Meet our Team

See our Catalog